Literature DB >> 11134184

Overexpression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production.

C Wu1, D A Okar, C B Newgard, A J Lange.   

Abstract

Hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is an important regulatory enzyme of glucose metabolism. By controlling the level of fructose-2,6-bisphosphate, an allosteric activator of the glycolytic enzyme 6-phosphofructo-1-kinase and an inhibitor of the gluconeogenic enzyme fructose-1,6-bisphosphatase, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase regulates hepatic glucose output. We studied the effects of adenovirus-mediated overexpression of this enzyme on hepatic glucose metabolism in normal or diabetic mice. These animals were treated with virus encoding either wild-type or bisphosphatase activity-deficient 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase. Seven days after virus injection, hepatic fructose-2,6-bisphosphate levels increased significantly in both normal and diabetic mice, with larger increases observed in animals with overexpression of the mutant enzyme. Blood glucose levels in normal mice overexpressing either enzyme were lowered, accompanied by increased plasma lactate, triglycerides, and FFAs. Blood glucose levels were markedly reduced in diabetic mice overexpressing the wild-type enzyme, and still more so in mice overexpressing the mutant form of the enzyme. The lower blood glucose levels in diabetic mice were accompanied by partially normalized plasma triglycerides and FFAs, increased plasma lactate, and increased liver glycogen levels, relative to diabetic mice treated with a control adenovirus. Our findings underscore the critical role played by hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in control of fuel homeostasis and suggest that this enzyme may be considered as a therapeutic target in diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134184      PMCID: PMC198549          DOI: 10.1172/JCI11103

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Isolation of a cDNA for the catalytic subunit of rat liver glucose-6-phosphatase: regulation of gene expression in FAO hepatoma cells by insulin, dexamethasone and cAMP.

Authors:  A J Lange; D Argaud; M R el-Maghrabi; W Pan; S R Maitra; S J Pilkis
Journal:  Biochem Biophys Res Commun       Date:  1994-05-30       Impact factor: 3.575

Review 2.  Metabolic engineering with recombinant adenoviruses.

Authors:  P A Antinozzi; H K Berman; R M O'Doherty; C B Newgard
Journal:  Annu Rev Nutr       Date:  1999       Impact factor: 11.848

3.  Induction of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA by refeeding and insulin.

Authors:  A D Colosia; A J Marker; A J Lange; M R el-Maghrabi; D K Granner; A Tauler; J Pilkis; S J Pilkis
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

4.  Hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Use of site-directed mutagenesis to evaluate the roles of His-258 and His-392 in catalysis.

Authors:  A Tauler; K Lin; S J Pilkis
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

5.  Rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Properties of phospho- and dephospho- forms and of two mutants in which Ser32 has been changed by site-directed mutagenesis.

Authors:  I J Kurland; M R el-Maghrabi; J J Correia; S J Pilkis
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

6.  Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice.

Authors:  J Herz; R D Gerard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes.

Authors:  L Rossetti; A Giaccari; N Barzilai; K Howard; G Sebel; M Hu
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism.

Authors:  A Barberà; J E Rodríguez-Gil; J J Guinovart
Journal:  J Biol Chem       Date:  1994-08-05       Impact factor: 5.157

9.  CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes.

Authors:  K Murano; Y Inoue; M Emoto; K Kaku; T Kaneko
Journal:  Eur J Pharmacol       Date:  1994-03-21       Impact factor: 4.432

10.  Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA.

Authors:  M Miralpeix; E Carballo; R Bartrons; K Crepin; L Hue; G G Rousseau
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

View more
  18 in total

Review 1.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.

Authors:  Mark H Rider; Luc Bertrand; Didier Vertommen; Paul A Michels; Guy G Rousseau; Louis Hue
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

2.  Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Hang Xu; Vera Halim; Weiyu Zhang; Huan Wang; Yang-Yi Fan; Kuok Teong Ong; Shih-Lung Woo; Robert S Chapkin; Douglas G Mashek; Yanming Chen; Hui Dong; Fuer Lu; Lai Wei; Chaodong Wu
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

3.  Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.

Authors:  Xin Guo; Kefeng Xu; Jifeng Zhang; Honggui Li; Weiyu Zhang; Huan Wang; Alex J Lange; Y Eugene Chen; Yuqing Huo; Chaodong Wu
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

4.  MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.

Authors:  Mark D Erion; Paul D van Poelje; Qun Dang; Srinivas Rao Kasibhatla; Scott C Potter; M Rami Reddy; K Raja Reddy; Tao Jiang; William N Lipscomb
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

5.  Myeloid cell-specific disruption of Period1 and Period2 exacerbates diet-induced inflammation and insulin resistance.

Authors:  Hang Xu; Honggui Li; Shih-Lung Woo; Sam-Moon Kim; Vikram R Shende; Nichole Neuendorff; Xin Guo; Ting Guo; Ting Qi; Ya Pei; Yan Zhao; Xiang Hu; Jiajia Zhao; Lili Chen; Lulu Chen; Jun-Yuan Ji; Robert C Alaniz; David J Earnest; Chaodong Wu
Journal:  J Biol Chem       Date:  2014-04-25       Impact factor: 5.157

6.  Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia.

Authors:  Qianwen Wang; Rajakumar V Donthi; Jianxun Wang; Alex J Lange; Lewis J Watson; Steven P Jones; Paul N Epstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

7.  Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.

Authors:  Xin Guo; Honggui Li; Hang Xu; Vera Halim; Laura N Thomas; Shih-Lung Woo; Yuqing Huo; Y Eugene Chen; Joseph M Sturino; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-07-26       Impact factor: 6.048

8.  A role for inducible 6-phosphofructo-2-kinase in the control of neuronal glycolysis.

Authors:  Honggui Li; Xin Guo; Hang Xu; Shih-Lung Woo; Vera Halim; Caurnel Morgan; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-12-14       Impact factor: 6.048

9.  Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Huan Wang; Weiyu Zhang; Ying Wang; Huaijun Zhou; Zhanguo Gao; Sucheta Telang; Jason Chesney; Y Eugene Chen; Jianping Ye; Robert S Chapkin; Chaodong Wu
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

Review 10.  Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.

Authors:  Amy K Rines; Kfir Sharabi; Clint D J Tavares; Pere Puigserver
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.